Recent advances in intra-arterial thrombolysis

Eric M. Bershad, Jose I. Suarez

Department of Neurology, Neurocritical Care and Vascular Neurology, Baylor College of Medicine, Houston, TX USA.

Abstract

Thrombolytic therapy has revolutionized acute ischemic stroke (AIS) treatment; however it is clear that intravenous (IV) thrombolytic therapy has certain limitations, including a short-time window for use, poor specificity for the site of arterial occlusion, and suboptimal recanalization rates. Some of these problems may be circumvented by using intra-arterial (IA) thrombolysis. In this article, we will discuss the various thrombolytic agents being used in AIS, their mechanisms of action and doses, and the rationale for use of IA therapy as opposed to IV thrombolysis, and review the clinical trials using IA thrombolysis. We will also discuss other approaches to IA thrombolysis, including mechanical and other endovascular techniques.

Keywords

Acute stroke, cerebral angiography, endovascular, intra-arterial thrombolysis, rt-PA

Dynamic advances in acute ischemic stroke (AIS) treatment have changed the nihilistic approach of the past to one of energetic resolve. The success of the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study (NINDS rtPA) in 1995 paved the way for the clinical use of intravenous (IV) thrombolytic therapy for AIS. Although, IV rtPA has provided clinicians with a potent weapon in their arsenal against AIS, it is clear that it has limitations. Only a small percentage of patients with AIS receive IV rtPA. This may be related, in part, to the narrow inclusion criteria which limit treatment to within 3 h of symptoms and also the multiple exclusion criteria. Furthermore, IV rtPA given alone only produces recanalization in about 50% of patients. Because of these drawbacks, alternative approaches to thrombolytic administration have been explored. Intra-arterial (IA) thrombolysis using streptokinase for vertebrobasilar occlusion was reported in 1982. Since then, there have been many advances in IA thrombolysis, including the use of more specific thrombolytic agents, better endovascular devices and neuroimaging techniques, and improved protocols for selecting patients who may benefit from IA therapy. In this review, we will discuss the use of IA thrombolysis for AIS as an alternative or adjunct to IV thrombolysis and the rationale for its use; we will review the clinical trials that have been conducted, the protocols for its implementation, and the prospects for the future.

IA thrombolytic agents

Many thrombolytic agents have been used in AIS in IV or IA form. Each agent has its own properties with regard to half-life and fibrin specificity. Some of these agents include alteplase (rtPA), urokinase (u-PA), pro-urokinase (scu-PA), reteplase, desmoteplase, tenecteplase (TNK), streptokinase, staphylokinase, plasmin, and microplasmin. The only thrombolytic agent tested in a large randomized controlled fashion for IA use in AIS is recombinant pro-urokinase (scu-PA) (Prolyse), which was used in the Prolyse in Acute Cerebral Thromboembolism (PROACT I and II) trials; however the US Food and Drug Administration (FDA) did not approve this drug for use in the US based on the findings of these trials. The only thrombolytic approved by the FDA for use in AIS is IV rtPA used within 3 h of stroke onset based on the NINDS rtPA trial. IA urokinase has been reported in two small randomized controlled trials. IA reteplase has been used only in uncontrolled case series. Qureshi et al. reported good recanalization (88%) with reteplase in 16 consecutive patients who were not candidates for IV rtPA, while 44% had improvement of > 4 in NIHSS at 24 h; however, 56% died during hospitalization. The other thrombolytic agents including desmoteplase, tenecteplase, staphylokinase, streptokinase, plasmin, and microplasmin have not been tested in randomized controlled trials in the IA form. We present, in Figure 1,
Table 1: Characteristics of thrombolytic agents

| Agent          | Origin                                      | Dosing                                               | Half-life | Specificity                                      | Randomized clinical trials |
|----------------|---------------------------------------------|------------------------------------------------------|-----------|-------------------------------------------------|-----------------------------|
| Alteplase (rtPA) | Endogenous tPA gene expressed in Chinese hamster ovary cells | IV: 0.9 mg/kg, 10% bolus over 1 min and rest over 1 h; IV/IA: 0.6mg/kg IV, 15% bolus over 1 min and rest over 30 min. Max IA dose (20-25 mg) | 6 min     | Fibrin-bound plasminogen > systemic plasminogen | NINDS rtPA (IV) ATLANTIS (IV) ECASS 1and2 (IV) EMS bridging (IV/IA) [1,30-32] |
| Urokinase (UK)  | Derived from endogenous pro-UK              | IA: 50,000-250,000 units aliquots over 5-20 min, repeat dosing up to maximum of 1,000,000-2,000,000 units |           | Activates systemic and clot-bound plasminogen   | Ducrocq et al., randomized 27 patients to IV or IA urokinase Macleod et al., randomized 16 patients to IA urokinase or medical management[27,28] |
| Pro-UK (scu-PA) | Recombinant form of pro-UK derived from murine hybridoma cells | IA: 9 mg at a rate of 4.5 mg/h                       | 9 min     | More specific to clot-bound plasminogen compared to UK | PROACT I and II (IA)[1,24] |
| Reteplase      | Recombinant form of rtPA                   | 0.1-1 units aliquots; maximum 6-8 units              | 14-18 min | Less specific than rtPA to fibrin               | none                        |
| Tenecteplase   | Recombinant form of rtPA                   |                                                     | 17-20 min | More fibrin-specific than rtPA                  | No reported IA use in humans |
| Desmoteplase   | Derived from bat saliva                     |                                                     | >2 h      | Highly specific to fibrin compared to rtPA      | DIAS (IV) DEDAS (IV)[30,32] |
| Staphylokinase (SaK) | Recombinant form of Sak derived from S. aureus by expression in E. coli |                                                     |           | High specificity to clot-bound fibrin           | None                        |
| Streptokinase  | Derived from streptococcus                 |                                                     |           | Binds to systemic and clot-bound plasminogen    | MAST-E (IV) MAST-I (IV) ASK (IV)[30] |
| Microplasmin   | Truncated from plasmin                      |                                                     |           | None                                            | None                        |
| Plasmin        | Endogenous                                 |                                                     | 0.1 sec   | Specifically degrades clot fibrin due to rapid inactivation by circulating antiplasmin | None                        |

Figure 1: A 61-year-old right-handed man experienced sudden-onset right hemiplegia and muteness of 3.5 h duration. NIHSS was 22. Head CT scan was normal. Cerebral angiography showed complete occlusion of the proximal left MCA (panel A). The patient received IA UK with complete recanalization of the left MCA (panel B) and resolution of his neurological deficits.

Randomized Clinical Trials using IA Thrombolysis

The PROACT-I and PROACT-II clinical trials were the first randomized trials to evaluate IA thrombolysis. PROACT II, the larger of these trials, randomized 180 patients with AIS from a middle cerebral artery occlusion to either IA pro-UK and IV heparin (n = 121) or IV heparin alone (n = 59). Mechanical disruption was not allowed in either group. The primary endpoint, an mRS score of 2 or less at 90 days, occurred in 40% of IA pro-UK patients and 25% of control patients (P = 0.04). Recanalization was seen in 66% and 27% of the pro-UK and placebo groups, respectively (P < 0.001). Mortality...
rates were similar in both groups: 25% and 27% for the IA pro-UK and placebo arms, respectively. Symptomatic intracerebral hemorrhage (ICH) was more common (10%) in the IA pro-UK arm than in the placebo arm (2%) ($P = 0.06$).

Thus far, this is the only large randomized and controlled clinical trial demonstrating the efficacy of IA thrombolysis. A meta-analysis of PROACT-I and PROACT-II showed that the risk reduction of being dead or independent with IA therapy has a wide confidence interval, which suggests that the benefit of thrombolysis may be either minimal or substantial. This issue can be clarified only by a much larger randomized controlled clinical trial.

The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) randomized 114 patients in Japan with middle cerebral artery stroke within 6 h to IA UK or standard therapy. No intravenous thrombolysis was allowed in either group. Adjunctive mechanical disruption of clot was allowed in the UK group. The study was stopped prematurely once IV thrombolysis became available in Japan. The primary endpoint of favorable outcome (mRS 0-2) at 90 days occurred more often in the IA group (49.1% vs 38.6%; OR: 1.54, 95% CI: 0.73 to 3.23; $P = 0.345$), but was not statistically significant. The preplanned secondary endpoint of excellent outcome (mRS 0-1) at 90 days was significantly higher in the UK group (42.1% vs 22.8% OR: 2.46, 95% CI: 1.09 to 5.54; $P = 0.045$).

It should be noted that the MELT trial randomized patients with a lower baseline stroke severity compared to the PROACT-II trial (NIHSS 14 vs 17) and treated patients earlier; this may partially explain the lack of statistical significance for the primary endpoint (mRS 0-2 at 90 days) in the MELT trial. Furthermore, the MELT study may have been underpowered to detect a difference between groups due to the premature termination of the study once IV thrombolysis became available in Japan.

Ducrocq et al. conducted a small randomized multicenter trial comparing IV UK vs IA UK given within the first 6 h of AIS.

Patients received 900,000 U of UK via IV ($n = 14$) or IA ($n = 13$) routes. Due to safety concerns the study was stopped early. A total of 7 patients (26%) died: 4 in the IV group and 3 in the IA group. Although the authors reported a greater and earlier improvement in the IA group, there was no difference in the main outcomes studied.

Macleod et al. conducted a small randomized study of 16 patients with angiographic evidence of posterior circulation vascular occlusion. Patients were evaluated within 24 h of symptom onset and received either IA scu-PA or conservative management. Fifty percent (4/8) of the patients in the IA group had good outcomes compared to 12.5% (1/8) in the control group; there was a baseline group imbalance, with more severe strokes in the IA-treated group.

### Comparison of IV vs IA Thrombolysis

Although IV rtPA improves patient outcomes when used within 3 h in AIS, it has important limitations. The main advantages of IV rtPA include relative ease of administration, widespread availability, and proven efficacy within 3 h of AIS. The main disadvantages of IV rtPA include its inability to provide any diagnostic information, a short-time window for use, inadequate recanalization rates, and poor specificity for the site of arterial occlusion. Potential advantages of IA thrombolysis include its ability to provide more accurate diagnostic information, better recanalization rates, and a potential to extend the therapeutic time window [Table 2].

### Limitations of IV Thrombolysis

The time window for efficacy of IV rtPA may vary from patient to patient, depending on factors related to the degree of ischemia, presence of collateral flow, and the severity of the stroke.

| Efficacy time window | Intravenous | Intra-arterial |
|----------------------|-------------|---------------|
| Availability         | < 3 h       | < 6 h         |
| Diagnostics          | Relatively available | Better |
| Time to treatment    | Limited     | Delayed       |
| Recanalization rate  | Quicker     | Better        |
| Relative efficacy    | Suboptimal  | IA pro-UK best |
| Safety in randomized | rtPA better | neurological outcomes than placebo |
| clinical trials*     | neurological outcomes | outcomes |
|                      |             | than IV heparin |
|                      |             | alone group within |
|                      |             | 6 h; higher rate of symptomatic ICH in rtPA |
|                      |             | group |

*Direct comparisons of efficacy and safety of IV vs IA thrombolysis unknown.
ischemic penumbra; however, the randomized clinical trials using IV rtPA for AIS have failed to demonstrate efficacy after 3 h from onset of symptoms. These failed trials include the European Cooperative Acute Stroke Studies (ECAS I and ECAS II) and Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS).

The ECAS I and II trials allowed IV rtPA to be given for up to 6 h. The ATLANTIS trial initially allowed treatment with IV rtPA for up to 6 h but later limited treatment to 3-5 h due to a high rate of symptomatic brain hemorrhage. Although no single randomized clinical trial has shown efficacy for IV rtPA after the 3-h time window, a meta-analysis showed benefit from IV therapy up to at least 4.5 h.[36] There are several ongoing clinical trials to determine which subset of AIS patients may benefit from an extended time window. One should not conclude that IV tPA is any less effective than IA therapy after the 3-h time window, as no randomized clinical trials have directly compared these two treatments.[37]

The standard protocol for giving IV rtPA does not require direct visualization of the clot or evaluation of vascular anatomy such as collateral circulation. The only imaging study required before giving rtPA is a noncontrasted head CT.[31] While this may be time efficient, it leaves much to be desired in terms of diagnostic accuracy of clot location, collateral blood flow, ischemic penumbra, and potential time window for efficacy of treatment. In a review of angiography and stroke, it was found that 28% of patients with expected occlusions had no occlusion on angiography.[41] It is very likely that many of the cases in which no occlusion was found, had either spontaneous recanalization or an alternative diagnosis to explain the stroke-like symptoms.

Angiography can also provide information on the status of the collateral circulation. The importance of collateral flow was reported by Roberts et al. in an analysis of the PROACT II trial, where they showed that improvement in outcome at 90 days in the IA group compared to placebo group occurred only in the IA-treated patients who had good collateral flow.[42] Additionally, Christoforidis et al. reported that presence of pial collaterals on angiography in IA-treated patients predicted decreased infarct size and better mRS score at hospital discharge.[43]

**Limitations of IA Thrombolysis**

The time to treatment for IA thrombolysis is longer compared to that of IV thrombolysis because there are logistical factors involved, such as the need to assemble the angiography team and confirm occlusion angiographically before administration of thrombolytics. Bourekas et al. reported a mean time to treatment of 1 h and 46 min in patients receiving IA thrombolysis within 3 h. One-third of these patients developed the stroke during cerebral angiography, which would make IA therapy quicker since most preliminary steps to IA thrombolysis had already occurred.[44] In another study, the average delay from arrival in the emergency room to IA thrombolysis was 130 min.[45] Once IA therapy commences, the average time to recanalization ranges from 1.9-2.8 h.[46] In contrast, a TCD study of IV rtPA-mediated thrombolysis showed recanalization within 1 h in 75% of patients.[47] One approach used to minimize the delay in thrombolysis using IA therapy is to use a combination of a reduced dose of IV rtPA (0.6 mg/kg) within 3 h and then continue therapy using IA thrombolysis in patients who do not respond to IV thrombolysis.[32,40,48,49]

Another disadvantage of IA thrombolysis is the invasiveness of angiography. However, the risk of serious complications is relatively low when the procedure is done by an experienced angiographer. In a large retrospective analysis of about 20,000 patients who underwent cerebral angiography at the Mayo clinic, stroke and death occurred in 0.15% and 0.06% of patients, respectively. TIA occurred in 2%. Other complications include access-site hematoma (4.2%); nausea, vomiting, or transient hypotension (1.2%); anaphylaxis (0.03%); and acute renal failure (0.04%). Stroke occurred more frequently in patients with underlying atherosclerotic disease (0.25%).[50]

The monetary cost of IA thrombolysis and associated hospitalization may be an issue; however, the cost savings resulting from decreasing stroke disability likely outweighs the initial expense of thrombolysis and acute...
hospitalization. A cost-utility analysis of IV rtPA in AIS showed significant cost savings in rtPA-treated Canadian patients.\[51\] The relative costs of IA vs IV thrombolysis for AIS have not been reported. Future clinical trials should also include cost-effectiveness analyses to determine whether IA therapy is feasible from a financial standpoint.

**Other IA Endovascular Therapies for AIS**

In addition to pharmacological thrombolysis, other IA approaches may be used either adjunctively with IV rtPA or as an alternative to it in some patients. Some of these endovascular approaches include mechanical disruption of clot, mechanical thrombectomy, clot aspiration, angioplasty and/or stent placement, ultrasound disruption, and laser therapy. Most of these techniques are considered experimental and should not be used routinely.

Mechanical disruption is frequently used adjunctively with IA thrombolysis and involves manipulation of the clot with a microguidewire or microcatheter.\[12,40,49\] One approach for mechanical disruption is described by Sorimachi et al., who analyzed outcomes in 23 consecutive patients with severe AIS with occlusions of the proximal MCA or distal ICA. These patients received IA thrombolysis with urokinase and adjunctive mechanical disruption using a combination of four different disruptive techniques. The various techniques involved advancing a microcatheter to the distal end of the clot and forcefully injecting a thrombolytic agent as the tip of the microcatheter is withdrawn proximally, passing a standard microcatheter or one with a J-shaped microguidewire tip back and forth through the clot, or rotating a J-shaped guidewire tip within the clot. With these techniques the authors reported recanalization rates of 100% and 91% for MCA and ICA occlusions, respectively, without significant procedural complications.\[52\]

Mechanical removal of clot involves trapping the clot in a device and withdrawing it to a safer site. One such device, the MERCI retriever, has a corkscrew-shaped tip that is driven into the clot and subsequently withdrawn, thus removing the clot from the site of occlusion. This device was FDA approved in 2004 based on a nonrandomized clinical trial.\[53\] In this study, 141 patients with AIS with symptoms up to 8 h and who were not eligible for IV rtPA were treated with the MERCI retriever device. The mean NIHSS was 20. Recanalization was achieved in 48% of patients. Favorable neurological outcome was seen in 46% of recanalized patients and only 10% of non-recanalized patients. Subsequently, ‘real world experience’ with the MERCI retriever was reported by Devlin et al. in 25 consecutive patients. These patients had a median NIHSS of 18 and occlusions of the MCA (52%), distal intracranial carotid (8%), or vertebrobasilar (8%) arteries. Most of the patients (60%) also received IA rtPA. Good recanalization was achieved in 56% of patients. The median NIHSS was 9 at 3 months. Nine patients (36%) died, all in the non-recanalized group.\[54\] To date, no randomized controlled trials of the MERCI retriever have been completed.

**Comparison of IA Thrombolysis with other Therapies**

Despite the theoretical advantages of IA thrombolysis over IV thrombolysis, there are currently no data from large randomized controlled trials to allow a head-to-head comparison.

Only the PROACT II study directly compared IA therapy to a control group in a randomized trial; however, in this study the control patients received IV heparin and an angiogram, both potentially hazardous. Recently, Mandava et al. analyzed a large number of reported case series of IA thrombolysis in AIS using rtPA, UK, pro-UK, or reteplase with regard to neurological outcome and mortality, controlling for baseline patient differences such as initial NIHSS and age.\[55\] They compared the outcomes of patients treated with IA therapy with predicted outcome and mortality based on historical controls using best medical management of AIS, which included IV thrombolysis. The authors identified 1117 patients treated in eight different countries from 1998 to 2006. IA therapies included thrombolysis with or without adjunctive therapies such as angioplasty, mechanical disruption, and intravascular ultrasound. Overall, the mean difference in mortality, comparing IA mortality vs best medical treatment-predicted mortality rate, was 0.19% and the mean difference in functional outcome was 0.35%. Thus, no significant differences were observed in functional outcome or mortality in this analysis between what was observed with IA therapy compared to what would be expected by best medical therapy. However, this was a retrospective analysis and each of the IA thrombolysis case series had different methodologies and, therefore, one can not draw firm conclusions about the efficacy of IA thrombolysis vs other therapies.

**Ongoing Clinical Trials using IA Therapies for AIS**

Several randomized clinical trials evaluating IA thrombolysis are ongoing. The Interventional Management of Stroke III trial (IMS-III) is randomizing patients with AIS within 3 h of onset to one of three treatment arms: IV rtPA (0.9 mg/kg), combination of
IV rtPA with adjunctive IA rtPA or MERCI retriever, or IA rtPA and intravascular ultrasound with the EKOS catheter.\[25\]

The MR Rescue Trial is a randomized controlled trial of the MERCI retriever vs standard care in patients with AIS from a large vessel MCA or ICA occlusion within eight hours of onset and a Diffusion-weighted (DWI) and perfusion-weighted (PWI) mismatch.\[53\]

The Local vs Systemic Thrombolysis for Acute Stroke (SYNTHESIS) trial is randomizing patients with MCA occlusion within 3 h to receive either IV rtPA or IA rtPA.\[25\] Once all of these studies are completed, we may have a better idea about the relative efficacy and safety of IA thrombolysis.

**Protocol for IA Thrombolysis**

Multiple protocols have been published to facilitate administration of IA thrombolysis; some of these employ IA thrombolysis with UK, scu-PA, or rtPA only, or a combination thrombolysis using a reduced dose IV rtPA within 3 h, followed by IA thrombolysis within 6 h of stroke onset. We endorse the recent recommendations issued by the American Stroke Association regarding IA thrombolysis for AIS.\[56\] Based on the published literature, IA thrombolysis with at least one agent (scu-PA) may benefit patients who present within 3-6 h after onset of AIS due to an MCA occlusion. The therapeutic window for patients with vertebral or basilar artery occlusion has not been established. There are anecdotal reports showing angiographic and clinical improvement up to 72 h after onset of stroke. It should be noted that the time window for success of thrombolysis is related to multiple factors, including collateral circulation, degree of ischemia, and site of occlusion. Other candidates for IA thrombolysis may include those patients who are evaluated within 6 h of symptoms and who are not eligible for IV therapy because of recent surgery or other procedures. Additionally, IA therapy should be given only in specialized centers with dedicated and properly trained endovascular personnel.

In our literature review, the thrombolytic agents most commonly used included rtPA, urokinase, and reteplase. The typical dose of IA rtPA is a maximum of 0.3 mg/kg or total dose of about 20-24 mg.\[32,40,49\] In our protocol, we give 5 mg of rtPA diluted in 10 ml normal saline and infused over 10 min and repeat this dose until good recanalization occurs or until the maximum rtPA dose is reached.\[40\] The dose of IA urokinase varies widely. Initial dose ranges from 50,000-250,000 units given as a bolus over 5-20 min; this dose may be repeated up to a maximum cumulative dose of 1,000,000 to 2,000,000 units of UK.\[12,40\] A protocol we have used gives an initial dose of 250,000 units IA UK diluted in 3 ml normal saline over 5 min; doses of 250,000 units UK over 20 min may be repeated until recanalization occurs or until a maximum dose of 1,500,000 units is reached.\[40\] The dosing of reteplase that has been reported in the literature is up to a maximum dose of 6-8 units given in aliquots of 0.1-1 units.\[5,12\]

In Table 3, we present the protocol for IA thrombolysis as practiced in our institution. It is important to note that our patients are enrolled into available clinical trials whenever possible, as the true safety and efficacy of IA thrombolysis is yet to be determined. The initial medical management of our protocol follows the recent guidelines issued for management of AIS by the American Heart Association/American Stroke Association.\[56\] These guidelines were based on the NINDS tPA guidelines, with a few modifications.\[51\] When using the combination IV/IA protocol, we recommend giving a reduced dose of 0.6 mg/kg of rtPA, with 15% of the calculated dose given as a bolus and the rest over 30 min. For example, in a 70 kg person, the total dose of IV rtPA would be 0.6 mg/kg × 70 kg = 42 mg. Of the 42 mg, 15% (i.e., 0.15 × 42 mg) or ~6 mg is given as a bolus and 36 mg (42 mg − 6 mg) is given as a 30-min infusion. One study reported the relative safety of giving full-dose (0.9 mg/kg) IV rtPA followed by IA thrombolysis in patients poorly responsive to IV therapy.\[57\] One should be aware that the optimum dose in combination IV/IA therapy has not been established. It may be prudent to give the full dose of IV tPA within 3 h if the endovascular team is not immediately available. On the other hand, if angiography can proceed rapidly, then one can give a reduced dose of IV tPA followed by up to 0.3 mg/kg of IA tPA.

Once the IV rtPA is started, the patient should be transferred quickly to the center where angiography will occur. Care should be taken to manage elevated blood pressure or hypotension and airway protection must be ensured. The blood pressure should be checked every 15 min before and during thrombolysis and for at least 2 h post-thrombolysis.

Once the patient arrives for IA thrombolysis, repeat NIHSS assessment should be done as recanalization may have occurred in some patients either spontaneously or due to the IV rtPA. Additional neuroimaging using MRI, CT, or TCD techniques before angiography can be considered on a case-by-case basis if more information is required. If agitation is present, the patient should be properly sedated before angiography. We recommend using short-acting agents so as not to interfere with the neurological assessment. One can use midazolam, lorazepam, or diazepam in small bolus doses in non-intubated patients or a propofol or midazolam drip in intubated patients. Access for IA thrombolysis is usually
via a femoral artery.

After IA thrombolysis, close neurological monitoring is mandatory. We recommend admitting patients to a neurointensivist-managed neuro-ICU if possible for at least 24 h. However, in the absence of resources a general ICU may be used. We repeat a non-contrasted head CT immediately after thrombolysis to look for post-thrombolysis intracerebral hemorrhage and repeat the scan 24 h post-treatment or earlier if neurological deterioration occurs. All patients should have neuroprotective measures instituted, including treatment of hyperglycemia and fever and management of blood pressure. We generally institute an insulin drip if two consecutive blood sugar readings are > 140 mg/dl. A temperature above 37.5°C should be treated with acetaminophen 650 mg every 4 to 6 h or external cooling if the temperature does not respond. Hypertension can be managed with 10 mg of IV labetalol, if necessary repeating labetalol at doubling doses every 10 min up to a maximum total dose of 150 mg. Alternatively, we use a nicardipine drip: 5 mg IV bolus followed by 5-15 mg/h infusion if elevated blood pressure is refractory to parenteral boluses of antihypertensives. Additionally, all patients should receive deep venous thrombosis prophylaxis with elastic hose and sequential compression stockings, with subcutaneous heparin added after the 24 h post-treatment head CT. We recommend starting early nutrition if swallowing evaluation indicates that it would be safe to do so. Once the patient has demonstrated neurological stability for at least 24 h and non-contrasted head CT shows no significant intracerebral hemorrhage, patients can be transferred to a regular hospital bed or step-down unit.

References

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: Emerging pharmacological, mechanical and imaging strategies. Stroke 2005;36:2311-20.
3. Zeumer H, Hacke W, Ringelstein EB. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. AJNR Am J Neuroradiol 1983;4:401-4.
4. Leker RR, Eichel R, Rafaeli G, Ben-Hur T. Novel therapies for acute ischemic stroke. Isr Med Assoc J 2006;8:788-92.

5. Qureshi AI, Ali Z, Suri MF, Kim SH, Shatil AA, Ringer AJ, et al. Intracerebral third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001;49:41-50.

6. Qureshi AI, Pande RU, Kim SH, Hanel RA, Kirmani JF, Yahia AM. Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Investig Drugs 2002;3:1729-32.

7. Lapchak PA, Song D, Wei J, Zivin JA. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 2004;188:279-85.

8. Comu C, Boutlitte F, Candelise L, Boissel JP, Donnan GA, Hommel M, et al. Streptokinase in acute ischemic stroke: An individual patient data meta-analysis: The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000;31:1555-60.

9. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-31.

10. Hacke W, Albers G, Al-Rawi Y, Boggusslawsky J, Davalos A, Eliaszw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.

11. Collen D, Lijnen HR. Thrombolytic agents. Throm Haemost 2005;93:627-30.

12. Sugg RM, Noser EA, Shanlton HM, Gonzales NR, Campbell MS, Weir R, et al. Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. AJNR Am J Neuroradiol 2006;27:769-73.

13. Arnold M, Schrotth G, Nedeltchek K, Loher T, Remonda L, Stepper F, et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 2002;33:1828-33.

14. Brekenfeld C, Remonda L, Nedeltchek K, Arnold M, Mattle HP, Fischer U, et al. Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: Assessment of 294 patients treated with urokinase. J Neuror Neuropysych 2007;78:280-5.

15. Ueda T, Sakaki S, Kumon Y, Ohta S. Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke. Stroke 1999;30:2360-5.

16. Pannell R, Gurewich V, Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986;67:1215-23.

17. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke, The PROACT study: A randomized controlled trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke: PROACT investigators, prolyse in acute cerebral thromboembolism. Stroke 1998;29:4-11.

18. Lapchak PA. Development of thrombolytic therapy for stroke: A perspective. Expert Opin Invest Drugs 2002;11:1623-32.

19. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: A novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002;33:2279-84.

20. Stroke Trials Registry. Internet Stroke Center website. [Last accessed on 2007 Sep]. Available from: http://www.strokecenter.org.

21. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke: PROACT investigators, prolyse in acute cerebral thromboembolism. Stroke 1998;29:4-11.

22. Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 2005;20:12-7.

23. Ducrocq X, Bracard S, Taillandier L, Axionnat R, Lacour JC, Guillemin F, et al. Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke. J Neuroradiol 2005;32:26-32.

24. Wardlaw JM, Zoppo G, Yamaguci T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003;3:CD000213.

25. Ogawa A, Morl E, Minematsu K, Taki W, Takahashi A, Nemoto S, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007;38:2633-9.

26. Saver JL. Intra-arterial fibrinolysis for acute ischemic stroke: The message of MELT. Stroke 2007;38:2627-8.

27. Lewandowski CA, Frankel M, Tomtack TA, Broderick J, Frey J, Clark W, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-605.

28. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.

29. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.

30. Clark WM, Wissman GW, Jhamandas JH, Madden KP, Hamilton SJ. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial, Alteplase Thrombolysis For Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:1017-25.

31. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51.

32. Clark WM, Wissman GW, Jhamandas JH, Madden KP, Hamilton SJ. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial, Alteplase Thrombolysis For Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:1017-25.

33. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.

34. Ciccone A, Valvasori L, Gasparotti R, Scaramonzi F, Ballabio E, Sierzi R. Deburning 7 myths that hamper the realization of randomized controlled trials on intra-arterial thrombolysis for acute ischemic stroke. Stroke 2007;38:2191-5.

35. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862-7.

36. Lee KY, Han SW, Kim SH, Nam HS, Ahn SW, Kim DJ, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke 2007;38:192-3.
Bershad, et al.: Intra-arterial thrombolysis

51. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: A Canadian healthcare perspective. Pharmacoeconomics 2001;19:927-36.

Source of Support: Nil, Conflict of Interest: Nil

Received: 13-10-2007, Revised: 19-11-2007, Accepted: 18-12-07

Annals of Indian Academy of Neurology - Supplement 2008